Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Randomized Trial of Subcutaneous vs Intravenous Nivolumab in Previously Treated Metastatic Clear Cell Renal Cell Carcinoma
2020-003655-15Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Cmin d28 (trough concentration at Day 28). Started Feb 2021; status: active.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2020-003655-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003655-15.